Salestools LogoSalestools
Salestools AI Agents
Solutions
Resources
Company
Pricing
Salestools Logo

Salestools

The #1 AI Agent for Sales teams and Go To Market teams. Sell more, faster, with less effort.

Product

  • AI Sales Agents
  • Intent Data
  • Technology Data
  • Visitor Tracking
  • Co-Pilot
  • Social Selling

Solutions

  • Customer Service
  • E-commerce
  • SaaS
  • Enterprise
  • Small Business

Resources

  • The Report
  • Documentation
  • API Reference
  • Help Center
  • Blog
  • Case Studies
  • Webinars

Company

  • About
  • Careers
  • Press
  • Contact
  • Partners

Our locations

  • New York, HQ
  • Bucharest, AI Research Lab
  • Zug, Switzerland

Β© 2026 Salestools. All rights reserved.

Data Terms & SecurityPrivacy PolicyTerms of ServiceAcceptable Use
All systems operational
Salestools LogoSalestools
Salestools AI Agents
Solutions
Resources
Company
Pricing
Back to Reports
Fundraising

Agilent Technologies

Agilent Technologies Raises $50B in Public

5301 Stevens Creek Boulevard, Santa Clara, CA 95051January 1, 20242 min read
Employees
18000+

Agilent Technologies Raises $50B in Public


Agilent Technologies has successfully raised $50B in a Public at a $52B valuation led by Public.


Company Overview


Agilent Technologies is a Life Sciences company headquartered in 5301 Stevens Creek Boulevard, Santa Clara, CA 95051, founded in 1999 with 18000+ employees.


Life sciences company


Fundraising Details


  • Amount Raised: $50B
  • Round Type: Public
  • Valuation: $52B
  • Date: 2024-01-01
  • Investors: Public

About Agilent Technologies


Life sciences company The company is positioned in the Life Sciences sector, serving a growing market with innovative solutions.


Key Information


  • Headquarters: 5301 Stevens Creek Boulevard, Santa Clara, CA 95051
  • Founded: 1999
  • Team Size: 18000+
  • Industry: Life Sciences

What This Means


This funding round demonstrates strong investor confidence in Agilent Technologies's vision and execution. The capital will likely be used to:


  • Scale Operations: Expand the team and operational capacity
  • Product Development: Enhance existing products and develop new features
  • Market Expansion: Enter new markets and strengthen presence in existing ones
  • Technology Investment: Invest in infrastructure and technology capabilities

Industry Context


The Life Sciences sector continues to attract significant investment as companies innovate to meet evolving market demands. Agilent Technologies's successful fundraising reflects the strong fundamentals and growth potential in this space.


Valuation Milestone


Reaching a $52B valuation marks an important milestone for Agilent Technologies, positioning the company among notable players in the Life Sciences industry.


Looking Ahead


With this new capital, Agilent Technologies is well-positioned to execute on its growth strategy and continue building innovative solutions in the Life Sciences space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.


This fundraising news was reported on 2024-01-01. For more information about Agilent Technologies, visit their headquarters at 5301 Stevens Creek Boulevard, Santa Clara, CA 95051.

Company Info

Headquarters
5301 Stevens Creek Boulevard, Santa Clara, CA 95051
Founded
1999
Team Size
18000+

Topics

Fundraising(2912)Public(771)Life SciencesAgilent Technologies

Share

Related Reports

Fundraising
Tebra

Tebra Raises $250M Growth Financing | Healthcare Practice Management Platform

Healthcare practice management platform Tebra secures $250 million in growth financing led by Hildred Capital for AI-driven automation.

SalesTools Research
SalesTools Research
Jan 12, 2026
0 min readβ€’$250M
Fundraising
Harmattan AI

Harmattan AI Raises $200M Series B | Defense Tech Unicorn at $1.4B Valuation

French defense tech company Harmattan AI secures $200 million Series B led by Dassault Aviation, reaching unicorn status.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min readβ€’$200M
Fundraising
AirNexis Therapeutics

AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment

Biotech AirNexis Therapeutics emerges from stealth with $200 million Series A for dual PDE3/4 inhibitor COPD therapy.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min readβ€’$200M

Turn your sales ideas into reality today

Start your 14-day Pro trial today. No credit card required.

Start building for free